Ironwood Pharmaceuticals is rated a Buy after a 14.5% decline driven by the CFO's resignation and insider selling. Read more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results